glp 1 compounded tirzepatide (GLP-1/GIP) weekly GLP Eli Lilly just issued a

Showing the single result Showing the single result Disclaimer for PMC Herbals: The information provided on PMC Herbals is for informational and educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment

Look for videos from verified health educators that show the slow injection technique and proper swirling method

Retatrutide wins that comparison more often than not

CrossRef Evaluation of Health Associations With HeightNormalised Abdominal Body Composition Indices: A SingleCentre CrossSectional Study Yupeng Liu, Hangqian He, Keyu Qian, Yufeng Huang, Xuemei Ao, Xudong Shi, Binye Ruan, Ru Xue, Xiaoyi Fu, Shuran Wang Journal of Cachexia, Sarcopenia and Muscle.2024

The demographic characteristics are shown in Table 2

Side-by-side compound comparison Receptor targets Tirzepatide GLP-1 + GIP (dual) Semaglutide GLP-1 only Retatrutide GLP-1 + GIP + Glucagon (triple) Half-life Tirzepatide ~5 days Semaglutide ~7 days Retatrutide ~6 days Dosing frequency Tirzepatide Once weekly Semaglutide Once weekly Retatrutide Once weekly Max studied dose Tirzepatide 15 mg / week Semaglutide 2.4 mg / week (Wegovy) Retatrutide 12 mg / week Peak weight loss Tirzepatide 22.5% (SURMOUNT-1, 72 wk) Semaglutide 15.8% (STEP-1, 68 wk) Retatrutide 24.2% (Phase 2, 48 wk) FDA status (June 2026) Tirzepatide Approved (T2D, obesity, OSA) Semaglutide Approved (T2D, obesity, CV risk) Retatrutide Investigational Phase 3 Head-to-head Tirzepatide 20.2% vs semaglutide 13.7% (SURMOUNT-5) Semaglutide Retatrutide Not yet head-to-head vs tirzepatide HFpEF benefit Tirzepatide Yes (SUMMIT, HR 0.62) Semaglutide Yes (STEP-HFpEF) Retatrutide Not yet studied Unique advantage Tirzepatide Best-in-class FDA-approved efficacy